Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Organisation › Details

Nouscom (Group)

Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: > NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. > NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI). > NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2025. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. *

 

Period Start 2016-05-17 existent
Products Industry cancer vaccine
  Industry 2 drug development
Persons Person Udier-Blagovic, Marina (Nouscom 202002– CEO joined 201609 as COO before Versant Ventures + Novartis + McKinsey)
  Person 2 Muller, Tiffany (Nouscom 202407– promoted to CFO joined 2019 as VP Finance before Aramark)
     
Region Region Basel BS
  Country Switzerland
  Street 18 Bäumleingasse
  City 4051 Basel
  Tel +41-61-201-1831
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Nouscom AG. (7/17/24). "Press Release: Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development". Basel.
     
   
Record changed: 2024-12-29

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Nouscom (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top